Future Research Directions Improving the Chain of Recovery for Acute Stroke in Your Community.

Slides:



Advertisements
Similar presentations
Evidence-based Public Health Interventions Robert S. Lawrence, MD Bloomberg School of Public Health Johns Hopkins University April 20, 2005.
Advertisements

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Accomplishments in Stroke Care
Can we prevent stent restenosis after coronary stent implantation
Stroke Care in Europe L. Garcia-Castrillo, MD, SEMES Department of Emergency Medicine University Hospital Marques de Valdecilla Cantabria, Spain.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical.
Andy Jagoda, MD, FACEP The Role of Emergency Medicine in Neurologic Emergencies Andy Jagoda, MD, FACEP Professor of Emergency Medicine Mount Sinai School.
© Continuing Medical Implementation ® …...bridging the care gap Cardiovascular Disease in the Elderly Patient A Global Perspective.
Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Secondary prevention after a TIA or ischemic stroke.
به نام ايزد يکتا Clinical Trial Design Dr. Khalili 1  The common types  Advantages and limitations  Usual applications.
North Somerset Clinical Commissioning Group Priorities Dr Mary Backhouse Chief Clinical Officer.
European Society of Cardiology Cardiovascular diseases in women.
1 EFFECT STUDY 2 EFFECT STUDY  Set national cardiac care benchmarks for hospitals to work towards 
Cerebral Angiography for the Treatment of Cerebral Ischemia.
Changes in Radiology in preparation for the CSC Jonathon Priestley Acting Directorate Superintendent.
Animal Models of Stroke Are they valuable for discovering neuroprotective agents? Wu Li-ping
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation SPORTIF V Trial Presented at American.
ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.
Stroke David Hargroves, consultant stroke physician and clinical lead for stroke SEC CVD SCN.
Don Sims. Stroke Medicine  120,000 stroke in the UK  1.2 million living with the after effects of stroke  3 rd leading cause of death  Huge burdens.
N ational S troke R esearch I nstitute A Very Early Rehabilitation Trial (AVERT) Improving recovery and quality of life for stroke survivors Assoc Professor.
Northern England Strategic Clinical Network Conference 15 th May 2015 Stroke Update Elizabeth Morris Network Delivery Team Manager.
Edward C. Jauch, MD, MS FACEP 1 Research Horizons in the Acute Management of ICH.
In the Name of Allah Most Beneficent and Most Merciful.
Norwegian Vitamin Trial NORVITNORVIT Presented at The European Society of Cardiology Congress 2005 Presented by Dr. Kaare Harold Bønaa.
Judith Bennion - Nurse Manager (General Medicine) A Recipe for Care - Not a Single Ingredient.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
DR AMER JAFAR ‘STROKE’ October Ethnicity and recurrence of stroke Population-based study Compared poststroke recurrence and survival in Mexican.
Stroke by: Katarina Batinjan Mentor: A. Ž mega č Horvat.
Ebrictus Register St Coordination Strategies of Care across Stroke recovery: Proposals for Nursing Intervention in Primary Care Teresa Forcadell-Arenas.
Logo Authors & Affiliations : Josep L Clua-Espuny (1), Teresa Forcadell-Arenas (1), Rosa Ripolles-Vicente (1), Panisello-Tafalla(1), Antonia González-Henares.
OASIS-2 OASIS-2 OVERVIEW 10,141 patients evaluating Hirudin vs. Heparin and 3712 patients evaluating Warfarin vs. Standard Therapy International (16 Countries)
Long-term mortality and thrombolysis therapy after a first acute ischemic stroke: gender differences. Ebrictus II Study. Authors & Affiliations Clua-Espuny.
Thrombolysis for acute ischaemic stroke Clinical
The reflective clinical librarian June The reflective clinical librarian: evaluating the most effective ways of spending our searching time. prepared.
“When time is Brain” Advanced imaging techniques for stroke management XIX Symposium Neuroradiologicum October 10 th, 2010 Bologna Italy.
Pharmacy in Public Health: Levels of Disease Prevention Add course Date here.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.
Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:
NURS 432: Nursing Care in the Community
Angela Aziz Donnelly April 5, 2016
The impact of hyperacute blood pressure lowering on the early clinical outcome following intracerebral hemorrhage Ryo Itabashia, Kazunori Toyodaa,b, Masahiro.
Neurological Emergency Treatment Trials Network Six questions about the new network Robert Silbergleit, MD University of Michigan.
كلية العلوم الصحية بالليث
The Stages of a Clinical Trial
The SPRINT Research Group
NATURAL HISTORY OF DISEASE
Addressing the Challenges in Primary and Secondary Stroke Prevention
Endocrine Combinations in HR-Positive MBC: The Future Is Now
Modifying Disease Course in Alzheimer's Disease
Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.
Select Topics in Cardiovascular Medicine
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
Optimizing Outcomes in the Management of GIST
Oral Anticoagulants in AFa,b A Brief History.
Optimizing Patient Outcomes in IBD
Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?
Social & Environmental Determinants Risk & Protective Factors
Late Breaking Clinical Trials
Modified Rankin score 0-2
Extraordinary Cases of VTE Prevention in Patients With Cancer
Elevated Admission Plasma Glucose Following ACS
Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:
ACC 2003 Late Breaking Trials
Introducing 1000 Lives Plus
ECASS-II: intravenous alteplase in acute ischaemic stroke
Presentation transcript:

Future Research Directions Improving the Chain of Recovery for Acute Stroke in Your Community

Overview Disease understanding Genetics/Genomics/Proteomics Primary Prevention Cerebrovascular disease Stroke Secondary Prevention Acute Stroke Treatment Recovery and Rehabilitation

Overview Disease understanding Genetics/Genomics/Proteomics Primary Prevention Cerebrovascular disease Stroke Secondary Prevention Acute Stroke Treatment Recovery and Rehabilitation

Trial Preparation Now More Creative Methodology More Thorough Phase I and Phase II Studies

Trial Design Now Simpler Larger

Trial Design Now Simpler Larger $$$$$$

Disease Target Stroke SAH Stroke SAH +ICH

Trial Organization Academic Consortium Networks of Practicing Physicians

Ischemic Stroke Refining Thrombolysis Drug Dose Route Clot removal Neuroprotection Combination Early treatment Hypothermia

Research Community Increasingly, clinical trials will become a part of clinical practice.

Conclusions The distinction between research and practice will diminish

Conclusions The distinction between research and practice will diminish. The importance of rapid response and early intervention will NOT change.

Conclusions The distinction between research and practice will diminish. The importance of rapid response and early intervention will NOT change. Disability and death from stroke will be reduced in gradual decrements in an ongoing process.

Conclusions The distinction between research and practice will diminish. The importance of rapid response and early intervention will NOT change. Disability and death from stroke will be reduced in gradual decrements in an ongoing process. There will be a trial testing an intervention for every stroke patient.